SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (13475)8/17/1998 11:12:00 AM
From: EyeDrMike  Read Replies (2) | Respond to of 23519
 
Keep in mind,

VVUS expenses on the International side are low. Astra and Jenssen assume the cost of the sales force and advertising for these countries. In addition, VVUS gets the choice to assume the sales force either in part or in its entirety after the contract has run for 5 years.

If a sizeable international market is established by that time, VVUS steps in and assumes control over the sales force, and gets the whole pie.

Mike



To: RT who wrote (13475)8/17/1998 12:02:00 PM
From: VLAD  Read Replies (1) | Respond to of 23519
 
RT,

Thought I would expound on your list:

Country/Population in millions

United States 270.3
Brazil 170
Mexico 98.5
Phillipines 77.7
Thailand 60
South Korea 46.4
South Africa 42.8
Argentina 36.3
Canada 30.7
Sweden 8.9
Switzerland 7.3
Hong Kong 6.7
New Zealand 3.6
Singapore 3.5
Total 862.7

Current World Population: 6 billion

So we now are approved to sell MUSE to .8626/6=14.4% of the world population.

And Vivus can't keep up with international orders.

Look at the big picture.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News